CSL (CSL) Stock Overview

Engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. More details

CSL fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	2/6
Past Performance	4/6
Financial Health	5/6
Dividends	4/6

Rewards

Trading at 39.7% below our estimate of its fair value

Earnings are forecast to grow 11.65% per year

Earnings have grown 3.9% per year over the past 5 years

Analysts in good agreement that stock price will rise by 42.6%

Risk Analysis

CSL passed our risk checks.

CSL Community Fair Values

Create Narrative

See what 265 others think this stock is worth. Follow their fair value or set your own to get alerts.

Hoth Therapeutics

Jolt_Communications

Community Contributor

100% Patient Improvement in trial puts this $16M Biotech on the radar

Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.

View narrative

US$5.3

67.5% undervalued

Revenue growth p.a.

127

11 days ago

CSL

AnalystConsensusTarget

Based on Analyst Price Targets

Operational Improvements Will Unlock Biotech Potential And China Market Expansion

Key Takeaways Operational transformation and investment in innovation are expected to drive margin expansion, earnings growth, and faster introduction of high-value therapies. Market expansion, a focused business structure, and strong demand for plasma and specialty products support sustainable top-line growth and premium positioning.

View narrative

AU$284.79

30.1% undervalued

5.26%

Revenue growth p.a.

132

25 days ago

CSL

Ramsee

Community Contributor

CSL is undervalued in High Tax Scenario

CSL Limited: Fair Value Assessment Amidst Evolving US Tariff Scenarios Executive Summary This report provides an assessment of the fair value of CSL Limited (CSL) under various potential United States (US) tariff scenarios. CSL, a global biotechnology leader with significant operations in plasma therapies (CSL Behring), influenza vaccines (CSL Seqirus), and iron/nephrology treatments (CSL Vifor), faces potential impacts from evolving US trade policies.

View narrative

AU$263.33

24.4% undervalued

6.00%

Revenue growth p.a.

6 months ago

View Stock Community

CSL Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for CSL
Historical stock prices
Current Share Price	AU$199.00
52 Week High	AU$304.99
52 Week Low	AU$189.80
Beta	0.26
1 Month Change	-6.52%
3 Month Change	-16.47%
1 Year Change	-30.49%
3 Year Change	-29.75%
5 Year Change	-31.19%
Change since IPO	24,775.25%

Recent updates

CSL Limited's (ASX:CSL) Share Price Not Quite Adding Up

Sep 25

Is CSL Limited (ASX:CSL) Trading At A 43% Discount?

Aug 07

Here's Why CSL (ASX:CSL) Can Manage Its Debt Responsibly

Jun 14

Weekly Picks: 🧠 Alphabet’s AI edge, CSL’s pricing power, and a chip underdog

Apr 16

CSL is undervalued in High Tax Scenario

Apr 15CSL Behring: This is CSL's largest segment and the global leader (#1) in plasma therapies within an estimated US$30 billion industry.11 It focuses on researching, developing, manufacturing, and distri

Advancements In iNOMi Technology And HEMGENIX Will Strengthen Market Position

Feb 23 Advancements in plasma collection and operational efficiencies are set to reduce costs and improve CSL Behring's margins, potentially boosting overall earnings.

Should You Be Adding CSL (ASX:CSL) To Your Watchlist Today?

Jan 31

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 43% Above Its Share Price

Jan 10

With EPS Growth And More, CSL (ASX:CSL) Makes An Interesting Case

Nov 01

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Oct 05

Shareholder Returns

	CSL	AU Biotechs	AU Market
7D	-0.1%	-1.8%	0.2%
1Y	-30.5%	-29.7%	6.9%

Return vs Industry: CSL matched the Australian Biotechs industry which returned -29.7% over the past year.

Return vs Market: CSL underperformed the Australian Market which returned 6.9% over the past year.

Price Volatility

Is CSL's price volatile compared to industry and market?
CSL volatility
CSL Average Weekly Movement	5.7%
Biotechs Industry Average Movement	11.9%
Market Average Movement	9.0%
10% most volatile stocks in AU Market	19.4%
10% least volatile stocks in AU Market	3.5%

Stable Share Price: CSL has not had significant price volatility in the past 3 months compared to the Australian market.

Volatility Over Time: CSL's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1916	29,904	Paul McKenzie	www.csl.com

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants.

CSL Limited Fundamentals Summary

How do CSL's earnings and revenue compare to its market cap?
CSL fundamental statistics
Market cap	AU$93.96b
Earnings (TTM)	AU$4.57b
Revenue (TTM)	AU$23.67b

21.1x

P/E Ratio

4.1x

P/S Ratio

Is CSL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CSL income statement (TTM)
Revenue	US$15.56b
Cost of Revenue	US$7.48b
Gross Profit	US$8.08b
Other Expenses	US$5.08b
Earnings	US$3.00b

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

Feb 09, 2026

Earnings per share (EPS)	6.21
Gross Margin	51.93%
Net Profit Margin	19.30%
Debt/Equity Ratio	45.9%

How did CSL perform over the long term?

See historical performance and comparison

Dividends

2.2%

Current Dividend Yield

47%

Payout Ratio

Does CSL pay a reliable dividends?

See CSL dividend history and benchmarks

When do you need to buy CSL by to receive an upcoming dividend?
CSL dividend dates
Ex Dividend Date	Sep 09 2025
Dividend Pay Date	Oct 03 2025
Days until Ex dividend	21 days
Days until Dividend pay date	3 days

Does CSL pay a reliable dividends?

See CSL dividend history and benchmarks

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/09/29 15:00
End of Day Share Price	2025/09/29 00:00
Earnings	2025/06/30
Annual Earnings	2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CSL Limited is covered by 28 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Saul Hadassin	Barrenjoey Markets Pty Limited
Thomas Wakim	Bell Potter
Lyanne Harrison	BofA Global Research

CSL (CSL) Stock Overview

Rewards

Risk Analysis

100% Patient Improvement in trial puts this $16M Biotech on the radar

Operational Improvements Will Unlock Biotech Potential And China Market Expansion

CSL is undervalued in High Tax Scenario

CSL Limited Competitors

Clinuvel Pharmaceuticals

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Amgen

Price History & Performance

Recent News & Updates

CSL Limited's (ASX:CSL) Share Price Not Quite Adding Up

CSL Limited, Annual General Meeting, Oct 28, 2025

Upcoming dividend of US$1.62 per share

Consensus EPS estimates fall by 22%

Investor sentiment deteriorates as stock falls 20%

Recent updates

CSL Limited's (ASX:CSL) Share Price Not Quite Adding Up

CSL Limited, Annual General Meeting, Oct 28, 2025

Upcoming dividend of US$1.62 per share

Consensus EPS estimates fall by 22%

Investor sentiment deteriorates as stock falls 20%

CSL Limited to Report First Half, 2026 Results on Feb 02, 2026

High number of new directors

CSL Limited Announces Unfranked Dividend for the Period of Six Months Ended June 30, 2025, Payable on October 03, 2025

Final dividend of US$1.62 announced

CSL Limited Provides Earnings Guidance for the Year 2026

Full year 2025 earnings released: EPS: US$6.20 (vs US$5.47 in FY 2024)

Health Canada Authorized CSL's Andembry (Garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (Hae)

Is CSL Limited (ASX:CSL) Trading At A 43% Discount?

CSL Limited announces U.S. Food and Drug Administration Approves Csl's Andembry®? (Garadacimab-Gxii) Treatment Targeting Factor Xiia with Once-Monthly Dosing for All Patients from the Start

Here's Why CSL (ASX:CSL) Can Manage Its Debt Responsibly

CSL Vifor Announces England's Nice Recommends Filspari®? (Sparsentan) as A Treatment Option for IgA Nephropathy

Weekly Picks: 🧠 Alphabet’s AI edge, CSL’s pricing power, and a chip underdog

CSL is undervalued in High Tax Scenario

Upcoming dividend of US$1.30 per share

Advancements In iNOMi Technology And HEMGENIX Will Strengthen Market Position

CSL and Arcturus Therapeutics Announces Marketing Authorization Grant by European Commission Marketing Authorization for Kostaive (Arct-154), A Self-Amplifying Mrna Covid-19 Vaccine

European Commission Approves CSL's ANDEMBRY®? (Garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)

First half dividend of US$1.30 announced

First half 2025 earnings: EPS and revenues miss analyst expectations

Joy Linton Resumes the Role of Chief Financial Officer of CSL Limited

CSL Behring's Gene Therapy HEMGENIX®? (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

Should You Be Adding CSL (ASX:CSL) To Your Watchlist Today?

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 43% Above Its Share Price

CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE)

MD, CEO & Executive Director recently sold AU$1.1m worth of stock

With EPS Growth And More, CSL (ASX:CSL) Makes An Interesting Case

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

MD, CEO & Executive Director exercised options and sold AU$1.1m worth of stock

Upcoming dividend of US$1.45 per share

Final dividend of US$1.45 announced

Full year 2024 earnings: EPS misses analyst expectations

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

Now 21% undervalued after recent price drop

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

Now 20% undervalued

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

First half 2024 earnings: EPS misses analyst expectations

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

Now 22% undervalued

Now 21% undervalued

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

Upcoming dividend of US$1.29 per share at 1.4% yield